Paul Friedman

Paul A. Friedman is a businessperson who has been at the helm of 5 different companies and currently occupies the position of Chairman for Prelude Therapeutics, Inc. and Chairman, President & Chief Executive Officer at Madrigal Pharmaceuticals, Inc. Paul A. Friedman is also on the board of Incyte Corp. (former President, Chief Executive Officer & Director), Alexion Pharmaceuticals, Inc. and Gliknik, Inc. and Member of American Society for Clinical Investigation, Member of American Society for Biochemistry & Molecular Biology, Inc. and Member of American Society for Pharmacology & Experimental Therapeutic. Paul A. Friedman previously occupied the position of Director at Cerulean Pharma, Inc., President for DuPont Pharmaceuticals Research Laboratories, President-Research & Development at DuPont Merck Pharmaceutical Co., Senior Vice President of Merck Research Laboratories Massachusetts LLC and Associate Professor-Medicine & Pharmacology at Harvard Medical School. Dr. Friedman received an undergraduate degree from Princeton University and a doctorate from Harvard Medical School.